(2008). A: Treatment with a thiazolidinedione induced significant, reversible mitral regurgitation. Cardiovasc Diabetol
(2008). Braunwald E: State of the art: using natriuretic peptide levels in clinical practice.
(2008). DH: Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med
(2007). Loke YK, Furberg CD: Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care
(2002). M: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care
(2005). Parving HH: Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia
(2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
(2005). Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.
(2005). Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia
(2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet
(2006). Tajik AJ, Tsang TS: Left atrial size: physiologic determinants and clinical applications.
(2001). Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients.